Movement Alert|10x Genomics, Inc. Falls 5.01% in Regular Trading, Post-earnings target cuts and CEO share sale weigh on sentiment

Market Focus11-16 22:55

On November 16, 10x Genomics, Inc. fell 5.01% in Regular Trading, trading around $55.46 per share with turnover of $21.729 million.

The move coincided with continued digestion of the company’s latest quarterly results, post-earnings price-target reductions by several firms, and a recently disclosed CEO share sale that continued to pressure near-term sentiment.

In its latest quarterly report, 10x Genomics, Inc. posted a loss of $0.15 per share, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million topped forecasts near $148 million. The company also raised full-year revenue guidance to $625 million-$635 million, above the market view of $620.8 million. Even so, recent target-price revisions included UBS to $61 from $90, alongside prior cuts cited for Barclays and BofA, indicating valuation pressure remained the dominant market focus.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment